Physician profile
Avinash Ravipati
NPI 1528444379
$2,540.26
in general payments reported to CMS, 2019-2025
30 companies · $502 in 2025
The $502 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $122 · 2021: $917 · 2022: $395 · 2023: $211 · 2024: $393 · 2025: $502.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,106.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,106.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $443.89 | 2021-2025 | Freestyle Libre 3 |
| Novo Nordisk INC | $400.78 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $310.88 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $175.38 | 2021-2025 | |
| Dexcom, INC. | $159.68 | 2021-2025 | Dexcom G6 Transmitter |
| Sanofi-Aventis U.S. LLC | $152.97 | 2020-2024 | |
| Xeris Pharmaceuticals, INC. | $142.20 | 2020-2025 | Recorlev, Gvoke Hypopen |
| Amgen INC. | $88.85 | 2022-2025 | Repatha, Repatha, Tepezza |
| Daiichi Sankyo INC. | $88.45 | 2020-2021 | |
| Astrazeneca Pharmaceuticals LP | $56.43 | 2021 | |
| Recordati_rare_diseases_inc. | $52.07 | 2024 | Isturisa, Signifor Lar |
| Corcept Therapeutics | $46.79 | 2021-2025 | Korlym |
| Radius Health, INC. | $42.57 | 2024 | Tymlos |
| Pfizer INC. | $40.67 | 2020-2021 | |
| Insulet Corporation | $34.79 | 2025 | Omnipod |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Beta Bionics, INC. | $30.17 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Astellas Pharma US INC | $28.65 | 2021-2024 | Veozah |
| Clarus Therapeutics INC. | $27.65 | 2021 | |
| Amarin Pharma, INC. | $26.33 | 2021 | |
| Tandem Diabetes Care, INC. | $21.17 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Cequr Corporation | $20.52 | 2023 | Cequr Simplicity |
| Kowa Pharmaceuticals America, INC. | $19.55 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $19.30 | 2025 | |
| Ultragenyx Pharmaceutical INC. | $18.50 | 2021 | |
| Sunovion Pharmaceuticals INC. | $17.53 | 2021 | |
| Amneal Pharmaceuticals LLC | $16.27 | 2022 | |
| Esperion Therapeutics, INC. | $16.25 | 2022 | |
| Medtronic, INC. | $15.14 | 2024 | Minimed 780g |
| Merck Sharp & Dohme LLC | $14.33 | 2021 | |
| Lifescan, INC. | $12.50 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Avinash Ravipati listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.